Makani Science

Makani Science

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Makani Science is a private, pre-revenue medical device company focused on reinventing respiratory monitoring. Its core technology is a wearable patch sensor that wirelessly transmits real-time breathing waveforms to mobile platforms, enabling immediate detection of respiratory events. The company targets the growing market for monitoring patients undergoing sedation or opioid therapy, addressing a critical need to prevent respiratory failure. Its leadership includes experienced engineers and a CEO with a background in bringing medical devices to market.

AnesthesiologyPost-operative CareRespiratory Monitoring

Technology Platform

Wearable patch sensor for continuous, wireless, noninvasive monitoring of respiratory rate, relative tidal volume, and minute ventilation. Data is transmitted in real-time to mobile platforms for clinical display.

Opportunities

The company targets the large and growing market for respiratory monitoring, driven by the expansion of outpatient surgeries using sedation and the ongoing need to manage opioid-related respiratory depression.
Its wearable, real-time solution addresses a critical gap in patient safety between intermittent checks and intensive care unit monitoring.

Risk Factors

Key risks include the technical challenge of accurately measuring tidal volume noninvasively, the regulatory hurdle of obtaining FDA clearance, and the commercial challenge of displacing established monitoring practices.
The company must also demonstrate clinical utility and secure adoption in a competitive market.

Competitive Landscape

Makani competes in the broad respiratory monitoring device market against large incumbents like Medtronic, Philips, and Masimo, as well as startups. It must differentiate from standard capnography and pulse oximetry by offering continuous volumetric data (tidal volume) in a wearable form factor, targeting earlier detection of respiratory depression.